Family Site

The contents provided by this page are intended only for Australian healthcare professionals.
Please leave this site if you are not an Australian healthcare professional.

Indications Dosing Administration Device Safety Information

Prescribing Remsima® SC

The only subcutaneous infliximab
formulation approved by TGA and EMA.1

Remsima® SC provides an alternative treatment option for patients with CD, UC, AS, PsA, PsO, and RA. 1

  • Availability of infliximab dual formulation as IV and SC provides a treatment that can be tailored to the individual needs of your patients.2

  • Remsima® SC offers comparable efficacy with stable potency and immunogenicity benefits to infliximab IV administration.3

References

1. Remsima® Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/Remsima®-epar-product-information_en.pdf Accessed 4 Sep 2020.

2. Jin, Jing-Fen et al. “The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. ” Patient preference and adherence vol. 9 923-42. 2 Jul. 2015, doi:10.2147/PPA.S87271

3. Ben-Horin S et al. A novel subcutaneous infliximab (CT-P13): 1-year results including a switch from intravenous infliximab (CT-P13) in patients with active Crohn’s Disease and Ulcerative Colitis. OP24. Presented at ECCO 2020, 12–15 February, Vienna.

Abbreviations

AS, ankylosing spondylitis; CD, Crohn's disease; EMA, European Medicines Agency; IV, intravenous; PsA, psoriatic arthritis; PsO, plaque psoriasis; RA, rheumatoid arthritis; SC, subcutaneous; UC, ulcerative colitis